| Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review L Khoja, D Day, TWW Chen, LL Siu, AR Hansen Annals of Oncology 28 (10), 2377-2385, 2017 | 793 | 2017 |
| A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker L Khoja, A Backen, R Sloane, L Menasce, D Ryder, M Krebs, R Board, ... British journal of cancer 106 (3), 508-516, 2012 | 303 | 2012 |
| Pembrolizumab L Khoja, MO Butler, SP Kang, S Ebbinghaus, AM Joshua Journal for immunotherapy of cancer 3, 1-13, 2015 | 298 | 2015 |
| Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study L Khoja, EG Atenafu, S Suciu, S Leyvraz, T Sato, E Marshall, U Keilholz, ... Annals of Oncology 30 (8), 1370-1380, 2019 | 240 | 2019 |
| AR signaling and the PI3K pathway in prostate cancer M Crumbaker, L Khoja, AM Joshua Cancers 9 (4), 34, 2017 | 191 | 2017 |
| Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma L Khoja, P Lorigan, C Zhou, M Lancashire, J Booth, J Cummings, ... Journal of Investigative Dermatology 133 (6), 1582-1590, 2013 | 159 | 2013 |
| Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2 LT Nguyen, SD Saibil, V Sotov, MX Le, L Khoja, D Ghazarian, L Bonilla, ... Cancer Immunology, Immunotherapy 68, 773-785, 2019 | 130 | 2019 |
| Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non–Small-Cell lung cancer A Zer, MR Sung, P Walia, L Khoja, M Maganti, C Labbe, FA Shepherd, ... Clinical lung cancer 19 (5), 426-434. e1, 2018 | 128 | 2018 |
| Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma L Khoja, C Maurice, MA Chappell, L MacMillan, AS Al-Habeeb, ... Cancer immunology research 4 (3), 175-178, 2016 | 104 | 2016 |
| Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma JS Manusow, L Khoja, N Pesin, AM Joshua, ED Mandelcorn Journal for immunotherapy of cancer 2, 1-4, 2014 | 97 | 2014 |
| The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma L Khoja, EG Atenafu, A Templeton, Y Qye, MA Chappell, S Saibil, D Hogg, ... Cancer medicine 5 (10), 2792-2799, 2016 | 93 | 2016 |
| Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma L Khoja, P Shenjere, C Hodgson, J Hodgetts, G Clack, A Hughes, ... Melanoma research 24 (1), 40-46, 2014 | 90 | 2014 |
| Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance L Khoja, P Lorigan, C Dive, U Keilholz, A Fusi Annals of Oncology 26 (1), 33-39, 2015 | 83 | 2015 |
| Circulating biomarkers in hepatocellular carcinoma KL Morris, JD Tugwood, L Khoja, M Lancashire, R Sloane, D Burt, ... Cancer chemotherapy and pharmacology 74, 323-332, 2014 | 78 | 2014 |
| Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients L Khoja, M Kibiro, UR Metser, C Gedye, D Hogg, MO Butler, EG Atenafu, ... British Journal of Cancer 115 (10), 1186-1192, 2016 | 65 | 2016 |
| Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma L Khoja, EG Atenafu, Q Ye, C Gedye, M Chappell, D Hogg, MO Butler, ... Oncology letters 11 (2), 1581-1585, 2016 | 42 | 2016 |
| Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre L Khoja, A McGurk, C O’Hara, S Chow, J Hasan European Journal of Cancer 51 (2), 233-240, 2015 | 34 | 2015 |
| Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer L Khoja, G Kumaran, YK Zee, N Murukesh, R Swindell, MP Saunders, ... Journal of clinical gastroenterology 48 (5), 430-434, 2014 | 32 | 2014 |
| Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases R Rabbie, N Ansari-Pour, O Cast, D Lau, F Scott, SJ Welsh, C Parkinson, ... Nature communications 11 (1), 4306, 2020 | 31 | 2020 |
| Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience MN Nicholas, L Khoja, EG Atenafu, D Hogg, I Quirt, M Butler, AM Joshua Melanoma Research 28 (6), 571-577, 2018 | 31 | 2018 |
Glen ClackSenior Medical Director, AstraZeneca在 astrazeneca.com 的电子邮件经过验证
